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LETTER TO THE EDITOR
Renoprotection and blood pressure
To the Editor: The study by Bidani et al elegantly Reply from the authors
demonstrated that in rats with 5/6 renal ablation block- In response to Dr. Porush’s criticisms of the conclu-
ade of the renin-angiotensin system (RAS) by either an sions of our study [1], we submit the following facts for
angiotensin-converting enzyme (ACE) inhibitor or by his consideration. Several lines of evidence indicate that
an angiotensin receptor antagonist provides renoprotec- an exaggerated glomerular transmission of hypertension
tion, proportionate to the degree of blood pressure (BP) plays a major role in the pathogenesis of the progressive
lowering, which was dose dependent [1]. The authors glomerulosclerosis (GS) observed in the 5/6 ablation
interpret the data to suggest that the renoprotection is model. Moreover, there is an excellent direct correlation
only through BP-dependent mechanisms. In fact, the title between precisely quantitated BP (continuous radiote-
of the article suggests that there was a lack of evidence lemetry) and GS indicating that 60 to 80% of the differ-
of BP-independent protection by RAS blockade after ences in GS between individual untreated animals can
renal ablation in this study. They appear to justify these be accounted for by BP differences (r 2 5 0.6 to 0.8)
conclusions because of the tight fit between the level of [2–4]. Given such a dominant effect of “BP load” on GS
BP control and the degree of protection as measured by in this model, accurate BP measurements are critical for
the amount of proteinuria and the percentage of glomer- valid interpretations, the BP-independent protection can
only be inferred if the observed protection provided byulosclerosis.
an agent is disproportionate to the achieved BP reduc-In the absence of another group of animals treated
tion. Such was not noted with either benazepril or losar-with a non-RAS blockading antihypertensive agent to
tan at any of the dosages.the same levels of blood pressure control as in the ani-
Dr. Porush considers such evidence insufficient formals reported, it is not possible to conclude that there
other antihypertensives. However, a lack of protectionis no role for BP-independent mechanisms associated
comparable to renin-angiotensin system (RAS) blockadewith RAS blockade in this renal model. Furthermore, it
may only indicate additional BP-independent deleteri-is not even possible, from the data presented, to conclude
ous effects of other antihypertensives [3]. In any event,that the renoprotection is primarily through BP-depen-
we have previously compared enalapril to both a stan-dent mechanisms, although that may be the case.
dard, and a high-dose triple therapy regimen (hydralaz-In addition to finding the title misleading, I was sur-
ine, hydrochlorothiazide and reserpine), using BP radio-prised that the authors did not even discuss the possibility
telemetry [4]. In contrast to the results obtained usingof BP-independent renoprotection in the ablation model
tail-cuff BP measurements, which have provided the pri-(as studied) except to state that a longer follow-up (they
mary evidence for BP-independent superiority of RASexamined these rats after seven weeks) might reveal BP-
blockade, glomeruloprotection in individual animals wasindependent pathways associated with RAS blockade.
found to be proportionate to the achieved BP reductions,They also noted that in other models, such as diabetes,
regardless of the antihypertensive regimen (r 5 0.91 forRAS may have more significant BP-independent effects.
all 34 rats). However, because of the antihypertensive
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